The Global Blood Plasma Derivatives Market is Growing Mainly Due to the Increasing Demand for Plasma Derived Products. According to a Recent Study Report Published by the Market Research Future.
Global Blood Plasma Derivatives Market - Competitive Analysis
Grigols (Spain), Baxter International Inc. (US), Octapharma AG (Switzerland), CSL Limited (Australia), Kedrion S.p.A (Italy), Bain Capital, LLC (US), Biotest AG (Germany), Fusion Healthcare (India), SK Plasma Co., Ltd. (South Korea) are some of the prominent players at the forefront of competition in the blood plasma derivatives market and are profiled in MRFR Analysis.
Also Read: https://www.medgadget.com/2019/07/blood-plasma-derivatives-market-to-cross-us-58-2-billion-by-2023-worldwide-industry-growth-at-7-52-cagr-with-analysis-by-size-share-segments-and-regional-trends-with-competitive-landscape-by-glob.html
Global Blood Plasma Derivatives Market - Overview
The Market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2018 – 2023.
Plasma is a fluid part of the blood that contains blood cells, and protein responsible for blood clotting. Plasma derivatives are obtained from specific plasma proteins by the process of fractionation. The derivatives are then solvent detergent-treated or heat-treated to kill certain viruses. The most common plasma derivative includes factor IX concentrate, factor VIII concentrate, anti-inhibitor coagulation complex (AICC), anti-thrombin III concentrate, immune globulins, Alpha 1-Proteinase inhibitor concentrate, albumin, and anti-thrombin III concentrate.
Blood plasma derivative widely used clinically to treat various conditions such as hemophilia A, hemophilia B, HIV, hepatitis B, hepatitis C, thrombocytosis, and others.
Other factors such as, rising incidence of hemophilia, huge funding for research & development, technological advancements, and rising approval from regulatory bodies are also fuelling the market growth. According to the Centers for Disease Control and Prevention, it is found that Hemophilia A affects 1 in 5,000 male births i.e. around 400 babies are born with hemophilia A every year.
Despite these drivers, stringent reimbursement policies, safety concerns, and high cost of treatment is expected to decline the blood plasma derivatives market growth.
The global blood plasma derivatives market is currently dominated by few players.
Grigols is one of them by holding a strong share in the market. The company’s stronghold is largely attributed to its innovative and sustainable products. Grigols aoperates in three major divisions i.e. Bioscience, Diagnostic and Hospital. On November 17, 2017 Grigols received FDA approval for a new genetic test used to detect alpha-1 antitrypsin deficiency. On November 11, 2013, Grifols acquired blood transfusion testing unit of Novartis AG for USD 1.68 billion. In the year 2016, Grifols has also acquired NAT (Nucleic Acid Testing) donor screening unit of Hologic for USD 1,850 million.
Baxter is also one of the leading player in blood plasma derivatives market. Baxter International Inc., the US based biopharmaceutical company, operates in two major segments, i.e. Hospital Products and Renal. Baxter’s product Bebulin (Factor IX Complex) is specifically used for the prevention, of hemorrhagic episodes in case of hemophilia B. Bebulin may carry a risk of transmitting infectious agents, such as viruses and, Creutzfeldt‐Jakob disease (CJD) agent.
Browse Complete Premium Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312